Table 1.

Efficacy of PSMA-TTC, varying doses of darolutamide, and their combinations in the ST1273 prostate cancer PDX model.

Response rate on day 100a
TreatmentT/C ratio on day 33CRPRSDPD
Darolutamide 15 mg/kgb,c0.60n.a.n.a.n.a.n.a.
Darolutamide 30 mg/kgb,d0.45n.a.n.a.n.a.n.a.
Darolutamide 100 mg/kgb,e0.60n.a.n.a.n.a.n.a.
PSMA-TTC 250 kBq/kg0.27**1/60/60/65/6
Darolutamide 15 mg/kg + PSMA-TTC 250 kBq/kg0.01***, ###, †7/91/91/90/9
Darolutamide 30 mg/kg + PSMA-TTC 250 kBq/kg0.01***, ###, †7/90/91/91/9
Darolutamide 100 mg/kg + PSMA-TTC 250 kBq/kg0.01***; ###, †9/101/100/100/10
  • Note: **, P < 0.01; ***, P < 0.001 in comparison with untreated control. ###, P < 0.001 in comparison with the corresponding darolutamide monotherapy. , P < 0.05 in comparison with the corresponding PSMA-TTC monotherapy.

  • Abbreviation: n.a., not applicable.

  • aResponses were determined according to RECIST.

  • bTreatment period for darolutamide: study days 0–20.

  • cLast study day 33.

  • dLast study day 36.

  • eLast study day 39.